TP53 and neoplasm: Indeed, early work established that small-molecule antagonists of the Mdm2-p53 interaction are effective in reactivating p53 tumor suppressor function in pre-clinical models7–9, and a variety of highly potent Mdm2-p53 antagonists (also called Mdm2 inhibitors) have since been developed and validated in vitro10.